Epimune GmbH

Epimune GmbH is a diagnostic company pioneering molecular immune cell quantification from a drop of blood. Immune cell enumeration is crucial for early detection and monitoring of patients with immune cell disorders, including primary immunodeficiencies, HIV infection, cancer, autoimmunity, autoinflammation and immunosuppression due to transplantation. Standard clinical practice calls for laboratory analysis of fresh blood samples by flow cytometry within 24 h after a venous blood draw. 

Using dried blood spots and proprietary real-time PCR-based test kits, Epimune enables clinical applications where fresh blood samples of sufficient quality and quantity for flow cytometric analysis are difficult or impossible to obtain – e.g. patient management in regions of limited laboratory and fresh blood transport infrastructure, at-home blood sampling, near-patient testing and newborn screening.

Epimune builds on technology developed over 15 years under the roof of Epiontis/A Precision for Medicine company and exclusively licensed to Epimune for in-vitro diagnostic (IVD) applications.

  • Mitarbeiterzahl

  • Kategorien
    • Auftragsforschung
    • Diagnostika-Entwickler
  • Gegründet

  • Aktualisiert am

Epimune GmbH 27. Januar 2021

Epimune GmbH and Tanner Pharma Group enter into Distribution Partnership for Latin America

Epimune GmbH, a molecular diagnostic company that develops, manufactures and commercializes in-vitro diagnostic tests for immune cell quantification from a drop of blood, announced today that it has entered into a license agreement with TannerLAC UK Limited ("TannerLAC"), a wholly owned subsidiary of Tanner Pharma Group for the i.Mune TBNK in-vitro diagnostic test in the Latin American region. TannerLAC provides pharmaceutical, biotech, and healthcare companies with a single-point partner for the commercialization of their products in challenging international markets.